Ionis Pharma (IONS): Market Capitalization-to-Revenue Ratio

Symbol and logo of brand Ionis Pharmaceuticals, Inc. (IONS)

Ionis Pharmaceuticals (IONS) relies on its own R&D centers while utilizing the capacity of contract manufacturing plants. Revenues are generated through royalties and licensing agreements with pharmaceutical behemoths. High-margin RNA therapy effectively blocks the synthesis of harmful proteins in genetic pathologies. The current status is 4.70, which is clearly demonstrated by the price-to-sales ratio chart.

IONS Ionis Pharmaceuticals: P/S Multiple in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for Ionis Pharma (IONS)

- stock value and consensus price forecast:
Stock Price ionispharma.com|IONS - Price Target Chart
- stock exchange capitalization data:
Market Value Ionis Pharma|IONS - Total Company Value
- book capitalization indicators:
Accounting Value per Share Ionis|IONS - Book Capitalization|Market Capitalization to Book Value Ratio ionispharma.com|IONS - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Ionis Pharmaceuticals|IONS - Long-Term Debt to Capital|Current Liabilities to Capital Isis Pharmaceuticals|IONS - Company Total Debt|Debts to Book Capitalization Ionis Pharma|IONS - Company Long-Term Liabilities|Amount of Current Liabilities Ionis|Interim Coverage Ratio ionispharma.com
- business earnings and investment ratios data:
IONS - Net Profit|Future Profit Ionis Pharmaceuticals|IONS - P/E Multiple|Forward P/E Multiple Ionis Pharmaceuticals, Inc.|IONS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ionis Pharma|IONS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Ionis|IONS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months ionispharma.com|IONS - Earnings per share growth in current year|Expected net earnings per share growth next year Ionis Pharmaceuticals
- issuer revenue and sales details:
IONS - Company Revenue|Company Revenue Forecast ionispharma.com|IONS - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Ionis Pharma
Summary company analytics:IONS ionispharma.com
Original product of Ionis

For Ionis Pharmaceuticals (IONS), whose business is based on scalable RNA therapeutics, this indicator reflects market expectations for the future monetization of patented developments relative to current revenues. By analyzing the price-to-sales ratio on the GURU.Markets platform, an investor assesses the extent of the premium paid for growth potential, comparing market capitalization with actual revenue to identify the gap between the speculative price and fundamental cash flows.

Who Ionis Pharmaceuticals competes with

P/S Multiple Tempus AI (TEM)|Price-to-Revenue Ratio Qiagen QGEN|Market Capitalization-to-Revenue Ratio RGEN|RNA - Price-to-Revenue Ratio|CRISPR (CRSP) - Market Cap to Revenue|WGS: P/S Multiple|ultragenyx.com (RARE) - P/S Multiple|BEAM (Beam Therapeutics) - P/S Multiple|Market Cap to Revenue Sarepta Therapeutics (SRPT)|P/S Multiple TWST|TXG - Price to Sales|Intellia Therapeutics - Market Cap to Revenue|P/S Multiple stoketherapeutics.com STOK|BLFS: Market Cap to Revenue|Wave Life Sciences Ltd - Market Cap to Sales Volume|MAZE: P/S Multiple|SION - Price-to-Revenue Coefficient|PRME (Prime Medicine, Inc.) - P/S Multiple|Market Cap to Revenue tayshagtx.com (TSHA)|P/S Multiple QURE|P/S Multiple MeiraGTx Holdings (MGTX)|Price-to-Revenue Ratio Regenxbio RGNX|Solid Corp - Price-to-Revenue Ratio|OCGN - Price-to-Revenue Ratio|Price-to-Revenue Coefficient pacb.com PACB|BNTC: P/S Multiple|DSGN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Rocket Pharmaceuticals Inc|Price to Sales 4D Molecular Corp FDMT|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|korrobio.com - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Editas Medicine EDIT|Price-to-Revenue Coefficient Silence Therapeutics PLC (SLN)|ProQR Therapeutics NV - P/S Multiple|CDXS (Codexis, Inc.) - Market Cap to Revenue Ratio|Sangamo Therapeutics (SGMO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio NAUT|MGX (Metagenomi) - P/S Multiple|P/S Multiple precisionbiosciences.com|P/S Multiple GBIO|Price-to-Revenue Coefficient Boundless Bio Inc|Price-to-Revenue Ratio Exicure XCUR|Imunon Inc (IMNN) - Price to Sales|PHIO - Price-to-Revenue Ratio|MBIO (Mustang Bio, Inc.) - Market Cap to Revenue Ratio|RNAZ: P/S Multiple|BNGO - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Applied DNA Sciences|bluebirdbio.com (BLUE) - Price-to-Revenue Coefficient|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|OMGA (Omega Therapeutics Inc) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|RGLS (Regulus) - Price-to-Sales Ratio|Syros Pharmaceuticals - P/S Multiple|Market Capitalization-to-Revenue Ratio TBIO (telesisbio.com)|TCON: P/S Multiple|Unity Biotechnology Inc. (UBX) - P/S Multiple